As investors continue to digest news regarding FDA concerns about overall survival trends of renal cell carcinoma patients in a Phase III trial with tivozanib, AVEO Oncology Inc. and Astellas Pharma Inc. have begun a Phase II study with the compound in triple-negative breast cancer.